March 12, 2018 / 4:17 PM / 2 months ago

BRIEF-Portola Pharmaceuticals Announces New Interim Results From Ongoing Annexa-4 Study

March 12 (Reuters) - Portola Pharmaceuticals Inc:

* PORTOLA PHARMACEUTICALS ANNOUNCES NEW INTERIM RESULTS FROM ONGOING ANNEXA-4 STUDY OF FACTOR XA INHIBITOR REVERSAL AGENT ANDEXXA® (ANDEXANET ALFA) IN PATIENTS WITH LIFE-THREATENING BLEEDING

* PORTOLA PHARMACEUTICALS INC - THE INTERIM RESULTS INCLUDED SAFETY DATA FROM 227 OF 228 ENROLLED PATIENTS

* PORTOLA PHARMACEUTICALS INC - EXCELLENT OR GOOD HEMOSTASIS ACHIEVED IN 83 PERCENT OF PATIENTS IN ANNEXA-4

* PORTOLA PHARMACEUTICALS INC - ANDEXANET ALFA IS CURRENTLY UNDER REVIEW BY U.S. FDA WITH AN ASSIGNED ACTION DATE OF MAY 4, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below